Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of central nervous system (CNS) disorders. The company's lead product candidate, AXS-05, is being developed for the treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD). Axsome Therapeutics was founded in 2012 and is headquartered in New York, New York.